Cardiac involvement in patients with spinal muscular atrophies
- PMID: 22616198
- PMCID: PMC3298107
Cardiac involvement in patients with spinal muscular atrophies
Abstract
The spinal muscular atrophies (SMAs) include a group of disorders characterized by progressive weakness of the lower motor neurons. Several types of SMAs have been described based on age onset of clinical features: Acute infantile (SMA type I), chronic infantile (SMA type II), chronic juvenile (SMA type III), and adult onset (SMA type IV) forms. The incidence is about 1:6,000 live births with a carrier frequency of 1:40 for the severe form and 1:80 for the juvenile form. The mortality and/or morbidity rates of SMAs are inversely correlated with the age at onset. SMAs are believed to only affect skeletal muscles; however, new data on SMA mice models suggest they may also impact the heart. Aim of the study was to retrospectively examine the cardiological records of 37 type molecularly confirmed II/III SMA patients, aged 6 to 65 years, in order to evaluate the onset and evolution of the cardiac involvement in these disorders. All patients had a standard ECG and a routine echocardiography. The parameters analysed were the following: Heart rate (HR), PQ interval, PQ segment, Cardiomyopathic Index (ratio QT/PQs), ventricular and supraventricular ectopic beats, pauses > or = 2,5 msec, ventricle diameters, wall and septum thickness, ejection fraction, fiber shortening. The results showed that HR and the other ECG parameters were within the normal limits except for the Cardiomyopathic Index that was higher than the normal values (2,6-4,2) in 2 patients. Left ventricular systolic function was within the normal limits in all patients. A dilation of the left ventricle without systolic dysfunction was observed in only 2 patients, aged respectively 65 and 63 years; however they were hypertensive and/or affected by coronary artery disease. Data here reported contribute to reassure patients and their clinicians that type II/III SMAs do not present heart dysfunction.
Similar articles
-
[Heart involvement in progressive spinal muscular atrophy. A review of the literature and case histories in childhood].Pediatr Med Chir. 1994 Mar-Apr;16(2):125-8. Pediatr Med Chir. 1994. PMID: 8078785 Review. Italian.
-
Cardiac function evaluation in children with spinal muscular atrophy: A case-control study.Pediatr Int. 2024 Jan-Dec;66(1):e15769. doi: 10.1111/ped.15769. Pediatr Int. 2024. PMID: 38742693
-
Cardiac function in types II and III spinal muscular atrophy: should we change standards of care?Neuropediatrics. 2015 Feb;46(1):33-6. doi: 10.1055/s-0034-1395348. Epub 2014 Dec 24. Neuropediatrics. 2015. PMID: 25539139
-
Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 3.Muscle Nerve. 2021 Jan;63(1):75-83. doi: 10.1002/mus.27088. Epub 2020 Oct 28. Muscle Nerve. 2021. PMID: 33043451
-
Disorders of the motor neurone.Baillieres Clin Neurol. 1994 Aug;3(2):431-45. Baillieres Clin Neurol. 1994. PMID: 7952856 Review.
Cited by
-
Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy.Mol Ther Methods Clin Dev. 2016 Sep 14;3:16060. doi: 10.1038/mtm.2016.60. eCollection 2016. Mol Ther Methods Clin Dev. 2016. PMID: 27652289 Free PMC article.
-
Spinal muscular atrophy: from tissue specificity to therapeutic strategies.F1000Prime Rep. 2015 Jan 5;7:04. doi: 10.12703/P7-04. eCollection 2015. F1000Prime Rep. 2015. PMID: 25705387 Free PMC article. Review.
-
Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development.Int J Mol Sci. 2021 Jul 23;22(15):7896. doi: 10.3390/ijms22157896. Int J Mol Sci. 2021. PMID: 34360669 Free PMC article. Review.
-
SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs.Skelet Muscle. 2020 May 8;10(1):16. doi: 10.1186/s13395-020-00232-7. Skelet Muscle. 2020. PMID: 32384912 Free PMC article.
-
Impact of missense mutations in survival motor neuron protein (SMN1) leading to Spinal Muscular Atrophy (SMA): A computational approach.Metab Brain Dis. 2018 Dec;33(6):1823-1834. doi: 10.1007/s11011-018-0285-4. Epub 2018 Jul 13. Metab Brain Dis. 2018. PMID: 30006696
References
-
- Pearn J. Classification of spinal muscular atrophies. Lancet. 1980;1:919–922. - PubMed
-
- Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–165. - PubMed
-
- Rochette CF, Gilbert N, Simard LR. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet. 2001;108:255–266. - PubMed
-
- Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177–1183. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical